SAT-049 Growth Hormone Treatment in Mexican Turner's Syndrome

Abstract

INTRODUCTION: Turner syndrome(TS) is a chromosomal disorder that occurs in one of every 2500 live births, characterized by the complete or partial absence of a chromosome X (the complete monosomy [45,X] accounts for more than 50% of cases), although some studies have found evidence of a high prevalence of mosaicism. It is associated with a range of phenotypic characteristics, chief of which are short stature, gonadal dysgenesis, hand and foot lymphoedema, pterygium colli, cubitus valgus and cardiovascular malformations, among others. Growth failure is a cardinal feature of TS, which may impair their quality of life, and adult patients have a mean height approximately 20 cm lower than that of unaffected women of the same ethnic group. METHODOLOGY: A study performed in the outpatient clinic of pediatric endocrinology of the National Institute for Pediatrics, descriptive, retrospective in 19 patients with Turner syndrome confirmed with karyotype, was followed up for 1 year in growth hormone treatment, size, weight was determined , Body mass index, growth rate at the beginning and at the end of the treatment. In addition, serum glucose, glycosylated hemoglobin was determined at the beginning and end of treatment. Statistical analysis was performed in the SPSS version program. RESULTS: We evaluated 19 patients with mean age 9 years +3.51, the average of the dose of growth hormone was of 1.43mg / day the size before treatment was an average of 114.73 with a SD:-3.06, showing improvement in the posterior size to treatment with an average of 119.25 SD:-2.7. In addition, the Body Mass Index was assessed with an average of 24.63 + 9.9 and at the end of treatment 27.98 +10.4. Regarding the growth rate, it is observed prior to the treatment Media 4.3 DE: 1.66 and the growth rate after the average treatment: 17.5 DE: 3.42 Levels of glycosylated hemoglobin (HBA1C) were assessed at the start of treatment with a mean of 5.3 (4.2- 5.7) and at the end of treatment the average of HBA1C 5.59 (4-6). DISCUSSION AND CONCLUSIONS: The short stature in TS is the fundamental finding and may be present in the absence of other clinical manifestations.The use of rhGH to increase the speed of growth and final height in patients with TS is an accepted and endorsed by different study. It has been observed in international studies that gains of 5-10cm are obtained with respect to the final size. It should start when the size is below -2 SDS with respect to the population mean or when the growth rate is lower than the 10th percentile for their bone age.The study that is presented is 12 months after the start of the treatment, an increase in the speed of growth as well.